Komori
TAUNS Laboratories (197A) · InitiativeFirst stated

Integrated In-House Structure from Planning and Development through Manufacturing and Sales

First written in FY2024. . Latest entry: FY2024.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
End-to-end in-house structure spanning research and development, manufacturing and salesA theme 8 companies write about · 0 as a headwind · 8 as a tailwind

0 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2024First statedAnnual report

    「By leveraging the strength of our integrated in-house system covering planning and development, manufacturing, and sales, we provide products that meet the broad needs of society, including those of medical institutions and patients.」

    The company positions coordination among product development, regulatory affairs, production, and sales in-house as a means of providing products and driving growth.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for TAUNS Laboratories yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Integrated In-House Structure from Planning and Development through Manufacturing and Sales | TAUNS Laboratories,Inc. (197A) | Komori